Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07255859 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AVIGA3 (Cohort 2.0)

Study acronym: AVIGA3
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 31, 2026 to Jul 31, 2027v3 Show 6 more changesShow less
    • Study completion pushed from Jul 31, 2027 to Dec 31, 2027
    • Interventions: Amsler Grid (Diagnostic Test), CRYSTALSIGHT (Device) to AVIGA (Device), Amsler Grid (Diagnostic Test)
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description shortened, about 7 words
    • Study title revised
    • Eligibility criteria shortened, about 2 words
  2. Site details revisedv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.
Trial Details
NCT Number NCT07255859
Lead Sponsor Tan Tock Seng Hospital
Conditions
(from sponsor)		 Maculopathy
Related terms Choroidal Neovascularization, Macular Degeneration
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov